

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited

和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2256)

**(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
(2) CHANGE IN COMPOSITION OF AUDIT COMMITTEE,
REMUNERATION COMMITTEE AND NOMINATION COMMITTEE;
AND
(3) MATTERS RELATING TO RULE 13.92 OF THE LISTING RULES**

The Board announces that with effect from February 28, 2025:

- (1) Mr. Wang Lei (王磊) has resigned as an independent non-executive Director of the Company and ceased to be a member of the Audit Committee and the chairperson of the Remuneration Committee of the Company;
- (2) Ms. Chui Hoi Yam (徐海音) has been appointed as an independent non-executive Director of the Company, and the chairperson of the Remuneration Committee and a member of the Audit Committee and Nomination Committee of the Company; and
- (3) The Company has satisfied the requirements for gender diversity for members of the Board under Rule 13.92 of the Listing Rules.

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Abbisko Cayman Limited (the “**Company**”) together with its subsidiaries, the “**Group**”) announces that, on February 28, 2025, Mr. Wang Lei (“**Mr. Wang**”) tendered his resignation as an independent non-executive Director of the Company and ceased to be a member of the Audit Committee and the chairperson of the Remuneration Committee of the Company with effect from February 28, 2025 due to his other commitments which require more of his dedication. Mr. Wang ceased to hold any position in the Company following his resignation.

Mr. Wang confirmed that he has no claim against the Company whatsoever whether in respect of fees, severance payments, expenses, damages, remuneration or compensation for the loss of office or otherwise and no disagreement with the Board, and there is no matter in respect of his resignation which needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the shareholders (the “**Shareholders**”) of the Company.

The Board would like to express its gratitude to Mr. Wang for his valuable contributions to the Company during his tenure of service.

The Board further announces that, on February 28, 2025, Ms. Chui Hoi Yam (“**Ms. Chui**”) has been appointed as an independent non-executive Director of the Company with effect from February 28, 2025. Ms. Chui shall hold office until the first annual general meeting of the Company after her appointment.

The biographical details of Ms. Chui are as follows:

Ms. Chui Hoi Yam (徐海音) (alias: 徐海瑛) (former name: 徐海英), aged 57. Ms. Chui is an independent non-executive Director, chairperson of the Remuneration Committee and member of the Audit Committee and Nomination Committee of Everest Medicines Limited (雲頂新耀有限公司), a company listed on the Stock Exchange of Hong Kong (stock code: 1952), since 19 January 2023. Ms. Chui was an executive director of China Biotech Services Holdings Limited (中國生物科技服務控股有限公司), a company listed on the GEM of the Honk Kong Stock Exchange (stock code: 8037), from December 2022 to June 2023 and was a non-executive director with effect from June 30, 2023 to June 13, 2024. Previously, she was the president of Harbin Pharmaceutical Group Co., Ltd. (哈藥集團股份有限公司) (“**Harbin Pharmaceutical**”), a company listed on the Shanghai Stock Exchange (stock code: 600664), from March 2019 to May 2022 and a director of Harbin Pharmaceutical from January 2021 to May 2022, where she was responsible for the overall business operation. Ms. Chui has also previously worked in China Hewlett-Packard Co., Ltd. (中國惠普有限公司) and Novartis International.

Ms. Chui received her bachelor’s degree in Economic Administration and master’s degree in Finance from Peking University, the People’s Republic of China in July 1990 and July 2001, respectively.

As at the date of this announcement, save as disclosed above, Ms. Chui (1) did not hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (2) does not have other major appointments or professional qualifications; (3) does not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined under the Rules Governing the Listing of Securities on the Honk Kong Stock Exchange (the “**Listing Rules**”)) of the Company; (4) does not hold any other positions with the Company or any of its subsidiaries; and (5) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Ms. Chui has entered into an appointment letter with the Company for a term of three years from February 28, 2025, subject to (i) re-election at the next annual general meeting of the Company and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company. According to the terms of Ms. Chui’s appointment, Ms. Chui will be entitled to receive a director’s fee of US\$50,000 per annum which is determined by reference to her experiences, duties and responsibilities, the prevailing market conditions and the remuneration policy of the Company. Ms. Chui will not be entitled to a discretionary bonus. Save for the emoluments relating to her role as an independent non-executive Director of the Company, Ms. Chui will not receive any emolument from the Group in respect of her other positions with the Company and other members of the Group.

Save as disclosed above, there is no information on any matter that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules nor any other matters in relation to the appointment of Ms. Chui that needs to be brought to the attention of the Shareholders or the Honk Kong Stock Exchange.

CHANGE IN COMPOSITION OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION COMMITTEE

The Board further announces that, (1) Ms. Chui has been appointed as the chairperson of the Remuneration Committee and a member of the Audit Committee and Nomination Committee of the Company with effect from February 28, 2025. The term of office of Ms. Chui as a member of the Board Committees is the same as her term of office as a Director; and (2) Dr. Sun Piaoyang has ceased to be a member of the Nomination Committee of the Company but continues to serve as a member of the Audit Committee of the Company and an independent non-executive Director of the Company, with effect from February 28, 2025.

The Board wishes to take this opportunity to congratulate Ms. Chui on her new role.

MATTERS RELATING TO RULE 13.92 OF THE LISTING RULES

Reference is made to the announcement of the Company dated December 20, 2024 in relation to, among other things, matters relating to the requirements for diversity of the Board under Rule 13.92 of the Listing Rules.

Following the appointment of Ms. Chui as an independent non-executive Director of the Company, the Company has satisfied the requirements for gender diversity for members of the Board under Rule 13.92 of the Listing Rules.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, February 28, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.